Literature DB >> 23970130

Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.

Sahir Kalim1, Hector Tamez, Julia Wenger, Elizabeth Ankers, Caitlin A Trottier, Joseph J Deferio, Anders H Berg, S Ananth Karumanchi, Ravi I Thadhani.   

Abstract

BACKGROUND AND OBJECTIVES: The mechanisms underlying erythropoietin resistance are not fully understood. Carbamylation is a post-translational protein modification that can alter the function of proteins, such as erythropoietin. The hypothesis of this study is that carbamylation burden is independently associated with erythropoietin resistance. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a nonconcurrent prospective cohort study of incident hemodialysis patients in the United States, carbamylated albumin, a surrogate of overall carbamylation burden, in 158 individuals at day 90 of dialysis initiation and erythropoietin resistance index (defined as average weekly erythropoietin dose [U] per kg body weight per hemoglobin [g/dl]) over the subsequent 90 days were measured. Linear regression was used to describe the relationship between carbamylated albumin and erythropoietin resistance index. Logistic regression characterized the relationship between erythropoietin resistance index, 1-year mortality, and carbamylation.
RESULTS: The median percent carbamylated albumin was 0.77% (interquartile range=0.58%-0.93%). Median erythropoietin resistance index was 18.7 units/kg per gram per deciliter (interquartile range=8.1-35.6 units/kg per gram per deciliter). Multivariable adjusted analysis showed that the highest quartile of carbamylated albumin was associated with a 72% higher erythropoietin resistance index compared with the lowest carbamylation quartile (P=0.01). Increasing erythropoietin resistance index was associated with a higher risk of death (odds ratio per unit increase in log-erythropoietin resistance index, 1.69; 95% confidence interval, 1.06 to 2.70). However, the association between erythropoietin resistance index and mortality was no longer statistically significant when carbamylation was included in the analysis (odds ratio, 1.44; 95% confidence interval, 0.87 to 2.37), with carbamylation showing the dominant association with death (odds ratio for high versus low carbamylation quartile, 4.53; 95% confidence interval, 1.20 to 17.10).
CONCLUSION: Carbamylation was associated with higher erythropoietin resistance index in incident dialysis patients and a better predictor of mortality than erythropoietin resistance index.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23970130      PMCID: PMC3817911          DOI: 10.2215/CJN.04310413

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  41 in total

1.  Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.

Authors:  Eugene O Apostolov; Sudhir V Shah; Ercan Ok; Alexei G Basnakian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-01-25       Impact factor: 8.311

Review 2.  Uremia.

Authors:  Timothy W Meyer; Thomas H Hostetter
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

3.  Impaired biological activity of erythropoietin by cyanate carbamylation.

Authors:  K C Mun; T A Golper
Journal:  Blood Purif       Date:  2000       Impact factor: 2.614

4.  Protein carbamylation links inflammation, smoking, uremia and atherogenesis.

Authors:  Zeneng Wang; Stephen J Nicholls; E Rene Rodriguez; Outi Kummu; Sohvi Hörkkö; John Barnard; Wanda F Reynolds; Eric J Topol; Joseph A DiDonato; Stanley L Hazen
Journal:  Nat Med       Date:  2007-09-09       Impact factor: 53.440

5.  Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL.

Authors:  Eugene O Apostolov; Sudhir V Shah; Debarti Ray; Alexei G Basnakian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-20       Impact factor: 8.311

6.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

7.  Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres.

Authors:  Alison Roche; Iain C Macdougall; Rowan G Walker
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

8.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

9.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Authors:  Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

10.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.

Authors:  James P Ebben; David T Gilbertson; Robert N Foley; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2006-09-06       Impact factor: 8.237

View more
  18 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

2.  Increased Synthesis of Liver Erythropoietin with CKD.

Authors:  Sophie de Seigneux; Anne-Kristine Meinild Lundby; Lena Berchtold; Anders H Berg; Patrick Saudan; Carsten Lundby
Journal:  J Am Soc Nephrol       Date:  2016-01-12       Impact factor: 10.121

3.  Reduction of carbamylated albumin by extended hemodialysis.

Authors:  Jeffrey Perl; Sahir Kalim; Ron Wald; Marc B Goldstein; Andrew T Yan; Nazanin Noori; Mercedeh Kiaii; Julia Wenger; Christopher Chan; Ravi I Thadhani; S Ananth Karumanchi; Anders H Berg
Journal:  Hemodial Int       Date:  2016-06-21       Impact factor: 1.812

4.  Protein carbamylation is a hallmark of aging.

Authors:  Laëtitia Gorisse; Christine Pietrement; Vincent Vuiblet; Christian E H Schmelzer; Martin Köhler; Laurent Duca; Laurent Debelle; Paul Fornès; Stéphane Jaisson; Philippe Gillery
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

Review 5.  Protein carbamylation in end stage renal disease: is there a mortality effect?

Authors:  Sahir Kalim
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-11       Impact factor: 2.894

6.  Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis.

Authors:  Sahir Kalim; Caitlin A Trottier; Julia B Wenger; Josh Wibecan; Rayhnuma Ahmed; Elizabeth Ankers; S Ananth Karumanchi; Ravi Thadhani; Anders H Berg
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 8.237

Review 7.  The Role of Nonenzymatic Post-translational Protein Modifications in Uremic Vascular Calcification.

Authors:  Kenneth Lim; Sahir Kalim
Journal:  Adv Chronic Kidney Dis       Date:  2019-11       Impact factor: 3.620

8.  The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure.

Authors:  Yossi Chait; Sahir Kalim; Joseph Horowitz; Christopher V Hollot; Elizabeth D Ankers; Michael J Germain; Ravi I Thadhani
Journal:  Hemodial Int       Date:  2016-02-03       Impact factor: 1.812

9.  The Effects of Parenteral Amino Acid Therapy on Protein Carbamylation in Maintenance Hemodialysis Patients.

Authors:  Sahir Kalim; Guillermo Ortiz; Caitlin A Trottier; Joseph J Deferio; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  J Ren Nutr       Date:  2015-03-05       Impact factor: 3.655

Review 10.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.